HC Wainwright Reaffirms Buy Rating for Tetraphase Pharmaceuticals (TTPH)

HC Wainwright restated their buy rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research report report published on Tuesday morning. HC Wainwright currently has a $17.00 target price on the biopharmaceutical company’s stock.

Several other analysts also recently commented on the stock. Stifel Nicolaus restated a buy rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Piper Jaffray Companies started coverage on shares of Tetraphase Pharmaceuticals in a report on Monday, August 28th. They set an overweight rating and a $14.00 target price on the stock. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a sell rating to a hold rating in a report on Saturday, October 28th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a hold rating to a sell rating in a report on Friday, September 1st. Finally, BMO Capital Markets raised their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the stock an outperform rating in a report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $15.15.

Shares of Tetraphase Pharmaceuticals (TTPH) traded up $0.10 during mid-day trading on Tuesday, reaching $5.84. 328,400 shares of the company’s stock traded hands, compared to its average volume of 707,221. Tetraphase Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $9.93.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). The firm had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The business’s quarterly revenue was up 355.6% on a year-over-year basis. During the same period last year, the company posted ($0.58) EPS. equities analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 earnings per share for the current fiscal year.

In other Tetraphase Pharmaceuticals news, Director L Patrick Gage acquired 3,880 shares of the stock in a transaction dated Wednesday, November 29th. The shares were bought at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now directly owns 38,880 shares of the company’s stock, valued at $250,776. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the sale, the insider now owns 8,750 shares in the company, valued at $52,762.50. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. California Public Employees Retirement System increased its holdings in Tetraphase Pharmaceuticals by 2.0% during the second quarter. California Public Employees Retirement System now owns 242,200 shares of the biopharmaceutical company’s stock worth $1,727,000 after buying an additional 4,800 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Tetraphase Pharmaceuticals by 6.5% during the first quarter. Schwab Charles Investment Management Inc. now owns 128,807 shares of the biopharmaceutical company’s stock worth $1,184,000 after buying an additional 7,866 shares during the last quarter. Vanguard Group Inc. increased its holdings in Tetraphase Pharmaceuticals by 16.4% during the first quarter. Vanguard Group Inc. now owns 1,638,789 shares of the biopharmaceutical company’s stock worth $15,061,000 after buying an additional 230,420 shares during the last quarter. Geode Capital Management LLC increased its holdings in Tetraphase Pharmaceuticals by 17.0% during the first quarter. Geode Capital Management LLC now owns 313,390 shares of the biopharmaceutical company’s stock worth $2,880,000 after buying an additional 45,554 shares during the last quarter. Finally, EcoR1 Capital LLC acquired a new position in Tetraphase Pharmaceuticals during the second quarter worth $4,516,000. Institutional investors own 58.19% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://ledgergazette.com/2017/12/08/hc-wainwright-reaffirms-buy-rating-for-tetraphase-pharmaceuticals-ttph.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply